🎉 M&A multiples are live!
Check it out!

PDS Biotechnology Valuation Multiples

Discover revenue and EBITDA valuation multiples for PDS Biotechnology and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

PDS Biotechnology Overview

About PDS Biotechnology

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.


Founded

2009

HQ

United States of America
Employees

24

Website

pdsbiotech.com

Financials

LTM Revenue n/a

LTM EBITDA -$38.2M

EV

$29.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

PDS Biotechnology Financials

PDS Biotechnology has a last 12-month revenue of n/a and a last 12-month EBITDA of -$38.2M.

In the most recent fiscal year, PDS Biotechnology achieved revenue of n/a and an EBITDA of -$33.8M.

PDS Biotechnology expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See PDS Biotechnology valuation multiples based on analyst estimates

PDS Biotechnology P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$40.1M -$33.8M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$40.9M -$42.9M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

PDS Biotechnology Stock Performance

As of April 15, 2025, PDS Biotechnology's stock price is $1.

PDS Biotechnology has current market cap of $49.0M, and EV of $29.2M.

See PDS Biotechnology trading valuation data

PDS Biotechnology Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$29.2M $49.0M XXX XXX XXX XXX $-1.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

PDS Biotechnology Valuation Multiples

As of April 15, 2025, PDS Biotechnology has market cap of $49.0M and EV of $29.2M.

PDS Biotechnology's trades at n/a LTM EV/Revenue multiple, and -0.8x LTM EBITDA.

Analysts estimate PDS Biotechnology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for PDS Biotechnology and 10K+ public comps

PDS Biotechnology Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $29.2M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.9x XXX XXX XXX
P/E -1.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PDS Biotechnology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

PDS Biotechnology Valuation Multiples

PDS Biotechnology's NTM/LTM revenue growth is n/a

PDS Biotechnology's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.5M for the same period.

Over next 12 months, PDS Biotechnology's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate PDS Biotechnology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for PDS Biotechnology and other 10K+ public comps

PDS Biotechnology Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -16% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

PDS Biotechnology Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

PDS Biotechnology M&A and Investment Activity

PDS Biotechnology acquired  XXX companies to date.

Last acquisition by PDS Biotechnology was  XXXXXXXX, XXXXX XXXXX XXXXXX . PDS Biotechnology acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by PDS Biotechnology

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About PDS Biotechnology

When was PDS Biotechnology founded? PDS Biotechnology was founded in 2009.
Where is PDS Biotechnology headquartered? PDS Biotechnology is headquartered in United States of America.
How many employees does PDS Biotechnology have? As of today, PDS Biotechnology has 24 employees.
Who is the CEO of PDS Biotechnology? PDS Biotechnology's CEO is Dr. Frank Bedu-Addo, PhD.
Is PDS Biotechnology publicy listed? Yes, PDS Biotechnology is a public company listed on NAS.
What is the stock symbol of PDS Biotechnology? PDS Biotechnology trades under PDSB ticker.
When did PDS Biotechnology go public? PDS Biotechnology went public in 2015.
Who are competitors of PDS Biotechnology? Similar companies to PDS Biotechnology include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of PDS Biotechnology? PDS Biotechnology's current market cap is $49.0M
What is the current EBITDA of PDS Biotechnology? PDS Biotechnology's last 12-month EBITDA is -$38.2M.
What is the current EV/EBITDA multiple of PDS Biotechnology? Current EBITDA multiple of PDS Biotechnology is -0.8x.
Is PDS Biotechnology profitable? Yes, PDS Biotechnology is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.